You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm's diagnostics revenues also grew 6 percent year over year with molecular diagnostics revenues up 9 percent.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.
Opko logged $181.1 million in revenues from services, $26.2 million in revenue from products, and $21.5 million from licensing and intellectual property.
The firm is looking to expand its sales internationally, as well as in the consumer-initiated market, but is being conservative with revenue growth estimates.
The firm is investing in commercial resources and research and development to capitalize on continued expansion in the global tuberculosis market, according to its CEO.
The firm said that total revenue was lower than expected due to the timing of orders in its flow cytometry operations in the third quarter.
The Temple City, California-based NGS genetic testing firm more than doubled its number of billable tests compared to the prior-year period.
The firm said it is tackling challenges in its Diagnostics business, which had 2 percent growth year over year on a comparable basis in its fiscal fourth quarter.
The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.